Development of new therapeutic approaches

LCC

 

 

 

Principal investigator: C. Esmieu/C. Hureau

Three main strategies are under focus. The first one is centered on the design of chelating compounds able to remove Cu from the amyloid-β. Various strategies are investigated: chelation of Cu(I) or/and Cu(II), impact of Zn(II) in Cu extraction from amyloid-β by chelators, importance of kinetics in Cu detoxification process, traceable chelation, use of metallated pro-drug as less-toxic surrogate of the chelators, chelation with additional abilities: artificial secretase, modulators of the assembly…

The second one relies on the use of natural and artificial chaperones, id est (bio-)molecules able to modulate the amyloid-β assembly process. Artificial chaperones include Re–based compounds, polyoxometallates, porphyrines, or Ln-complexes.

The third one aims at designing and investigating new (in vitro and in vivo) imaging tools to monitor the assembly process of the amyloid-β peptide and of other amyloid-forming peptides.

LCC

Laboratoire de chimie de coordination du CNRS

205 route de Narbonne, BP 44099
31077 Toulouse cedex 4
France

+ 33 5 61 33 31 00

Laboratoire de Chimie de Coordination
Privacy Policy

To improve your browsing experience. Cookies provide information on how the site is used: statistics such as the number of visitors, the average length of visits or the number of pages viewed. On the other hand, disabling cookies may prevent you from using certain features, such as sharing content via social networks.
By clicking "Accept", you agree to the use of cookies from this site and to our privacy policy.

You can adjust all your cookie settings by navigating the tabs on the left.